Mohammadi Shooka, Ziaei Somayeh, Morvaridi Mehrnaz, Hasani Motahareh, Mirtaheri Elham, Farsi Farnaz, Ebrahimi Sara, Daneshzad Elnaz, Heshmati Javad
Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran.
Department of Social and Preventive Medicine Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia.
Health Sci Rep. 2025 Mar 2;8(3):e70525. doi: 10.1002/hsr2.70525. eCollection 2025 Mar.
Patients with polycystic ovary syndrome (PCOS) commonly have cardiometabolic risk factors. Oxidative stress (OS) significantly contributes to the development of cardiometabolic diseases. Curcumin (CUR) exhibits antioxidant properties that aid in OS regulation. This systematic review and dose-response meta-analysis of randomized clinical trials (RCTs) evaluated the effects of CUR supplementation on cardiometabolic risk factors in women with PCOS.
A systematic search across various databases was implemented to identify eligible RCTs published until January 2024. A meta-analysis was conducted employing a random-effects model.
Eight RCTs were included in the meta-analysis. It was indicated that CUR supplementation substantially reduced fasting blood sugar (FBS) (standardized mean difference [SMD]: -0.40 mg/dL, 95% confidence interval [CI]: -0.59, -0.21; < 0.001), insulin (SMD: -0.32 µU/mL, 95% CI: -0.49, -0.14; < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (SMD: -0.36, 95% CI: -0.54, -0.19; < 0.001), and total cholesterol (TC) (SMD: -0.34 mg/dL, 95% CI: -0.61, -0.08; = 0.01). In addition, it substantially increased the quantitative insulin sensitivity check index (QUICKI) (SMD: 0.37, 95% CI: 0.13, 0.61; < 0.001) in the CUR-treated group compared with the control group. However, CUR did not have significant impacts on body mass index (BMI), body weight, serum levels of follicle-stimulating hormone (FSH), triglycerides (TG), dehydroepiandrosterone (DHEA), high-density lipoprotein (HDL), testosterone, low-density lipoprotein (LDL), and luteinizing hormone (LH).
This study revealed that CUR may have the potential to enhance cardiometabolic health by reducing hyperglycemia, insulin resistance, and serum TC levels in women with PCOS.
多囊卵巢综合征（PCOS）患者通常存在心脏代谢危险因素。氧化应激（OS）在心脏代谢疾病的发展中起重要作用。姜黄素（CUR）具有抗氧化特性，有助于调节OS。本系统评价和随机临床试验（RCT）的剂量反应荟萃分析评估了补充CUR对PCOS女性心脏代谢危险因素的影响。
对多个数据库进行系统检索，以确定截至2024年1月发表的符合条件的RCT。采用随机效应模型进行荟萃分析。
荟萃分析纳入了8项RCT。结果表明，补充CUR可显著降低空腹血糖（FBS）（标准化均数差[SMD]：-0.40mg/dL，95%置信区间[CI]：-0.59，-0.21；P<0.001）、胰岛素（SMD：-0.32µU/mL，95%CI：-0.49，-0.14；P<0.001）、胰岛素抵抗稳态模型评估（HOMA-IR）（SMD：-0.36，95%CI：-0.54，-0.19；P<0.001）和总胆固醇（TC）（SMD：-0.34mg/dL，95%CI：-0.61，-0.08；P=0.01）。此外，与对照组相比，CUR治疗组的定量胰岛素敏感性检查指数（QUICKI）显著升高（SMD：0.37，95%CI：0.13，0.61；P<0.001）。然而，CUR对体重指数（BMI）、体重、血清促卵泡激素（FSH）水平、甘油三酯（TG）、脱氢表雄酮（DHEA）、高密度脂蛋白（HDL）、睾酮、低密度脂蛋白（LDL）和黄体生成素（LH）没有显著影响。
本研究表明，CUR可能通过降低PCOS女性的高血糖、胰岛素抵抗和血清TC水平，具有改善心脏代谢健康的潜力。
